Black Diamond Therapeutics, Inc. Revenue 2018–2025
Black Diamond Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2018 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Black Diamond Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 0, a 100.00% decrease year-over-year.
- Black Diamond Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 70.0 M.
- Black Diamond Therapeutics, Inc. annual revenue for 2025 was 70.0 M.
- Black Diamond Therapeutics, Inc. annual revenue for 2024 was 0.
- Black Diamond Therapeutics, Inc. annual revenue for 2020 was 0.
- Black Diamond Therapeutics, Inc. annual revenue for 2019 was 0.
Black Diamond Therapeutics, Inc. (BDTX) — Frequently Asked Questions
Black Diamond Therapeutics, Inc. (BDTX) is a publicly traded US company. It has a market capitalization of $106M. In fiscal 2025 it reported revenue of $70M and net income of $22M. Explore BDTX's stock price, financial statements, earnings history, margins and key ratios below.
What is Black Diamond Therapeutics, Inc.'s market cap?
Black Diamond Therapeutics, Inc. (BDTX) has a market capitalization of $106M.
What is the BDTX stock price?
BDTX trades at $1.85 (-2.63% on the day).
How much revenue does Black Diamond Therapeutics, Inc. make?
Black Diamond Therapeutics, Inc. reported revenue of $70M in fiscal 2025.
Is BDTX profitable?
In fiscal 2025, Black Diamond Therapeutics, Inc. reported net income of $22M.